恶性疟裂殖子表面蛋白1合成基因在毕赤酵母中的表达

恶性疟原虫裂殖子表面蛋白1是当今疟疾疫苗主要的候选抗原。由于天然MSP1基因AT含量异常高(为74%),使得克隆全长天然基因无法实现。本文已全合成了msp1基因(4940bp),解决了该天然基因在异源系统中不稳定的问题。为制备大量msp1重组蛋白进行疫苗有效性试验,本研究建立了msp1基因在毕赤酵母中的表达,将合成的msp1基因克隆到毕赤酵母胞内表达载体pPIC3.5,构建了重组质粒pPIC3.5/msp1,用电击转化毕赤酵母得到重组转化子,经PCR证实msp1基因已整合于毕赤酵母染色体中。含有重组表达质粒的毕赤酵母菌经甲醇诱导后表达出全长msp1重组蛋白。表达产物能与识别MSP1分子二硫键依赖构象表位的特异性单抗发生很强的反应,表明msp1重组蛋白至少在该表位构象上与天然蛋白一致。从毕赤酵母中分离得到大量msp1为开展该蛋白的结构与功能,特别是测定其疟疾保护性免疫提供可能。     

毕赤酵母优化表达外源蛋白策略

毕赤酵母(Pichia pastoris)表达系统是一种异源蛋白表达的理想系统,但目前并非所有的外源蛋白都能在毕赤酵母中成功高效表达,不同的蛋白表现为不同表达水平、生物活性及稳定性。从遗传因素和表达条件综述了外源蛋白在毕赤酵母中的优化表达策略。     

Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production

Glycoengineering enabled the production of proteins with human N-linked glycans by Pichia pastoris. This study used a glycoengineered P. pastoris strain which is capable of producing humanized glycoprotein with terminal galactose for monoclonal antibody production. A design of experiments approach was used to optimize the process parameters. Followed by further optimization of the specific methanol feed rate, induction duration, and the initial induction biomass, the resulting process yielded up to 1.6 g/L of monoclonal antibody. This process was also scaled-up to 1,200-L scale, and the process profiles, productivity, and product quality were comparable with 30-L scale. The successful scale-up demonstrated that this glycoengineered P. pastoris fermentation process is a robust and commercially viable process.     

毕赤氏酵母工程菌高密度发酵表达恶性疟原虫融合抗原的研究

疟疾目前仍是危害人类健康的主要传染病,现全球每年新增疟疾病例3～5亿人,其中约300万人死于该病.特别是病原虫抗药性的产生和扩散已给疟疾防治工作带来极大困难,因此研制新的预防措施已成为当务之急.研制有效的疟疾疫苗被认为是人类控制乃至消灭疟疾的重要途径,已越来越受到重视,并已构建和鉴定多个疫苗候选抗原[1,2].本研究进行高密度优化表达的融合抗原就是一个疫苗候选抗原.     

Holistic process development to mitigate proteolysis of a subunit rotavirus vaccine candidate produced in Pichia pastoris by means of an acid pH pulse during fed-batch fermentation

To meet the challenges of global health, vaccine design and development must be reconsidered to achieve cost of goods as low as 15¢ per dose. A new recombinant protein-based rotavirus vaccine candidate derived from non-replicative viral subunits fused to a P2 tetanus toxoid CD4(+) T cell epitope is currently under clinical development. We have sought to simplify the existing manufacturing process to meet these aims. To this end, we have taken a holistic process development approach to reduce process complexity and costs while producing a product with the required characteristics. We have changed expression system from Escherichia coli to Pichia pastoris, to produce a secreted product, thereby reducing the number of purification steps. However, the presence of proteases poses challenges to product quality. To understand the effect of fermentation parameters on product quality small-scale fermentations were carried out. Media pH and fermentation duration had the greatest impact on the proportion of full-length product. A novel acidic pH pulse strategy was used to minimize proteolysis, and this combined with an early harvest time significantly increased the proportion of full-length material (60–75%). An improved downstream process using a combination of CIEX and AIEX to further reduce proteases, resulted in maintaining product quality (95% yield).     

Advances in the production of membrane proteins in Pichia pastoris

Membrane proteins play key roles in diverse cellular functions and have become the target for a large number of pharmacological drugs. Despite representing about 20-30% of cellular proteins, their characterization is long overdue since they are difficult to handle, to purify from their natural source or to obtain as recombinant proteins. Pichia pastoris is a methylotrophic yeast species increasingly used as a host for heterologous protein expression for both research and industrial purposes. Over the past few years many efforts have allowed important advances in the development of this expression system for the expression and production of membrane proteins. The most recent achievements in improving yield and proper folding of integral membrane proteins are summarized in this review.     

Cyclic fed-batch culture for production of human serum albumin in Pichia pastoris

Simple cyclic fed-batch culture (cfbc), consisting of a constant medium feed with periodic withdrawals of culture, resulted in a product yield (13.4 mg protein per gram biomass) similar to that obtained using the complex multiphase industrial production strategy (13.7 mg protein per gram biomass). In cfbc, productivity was ultimately limited by the rate at which the cells could assimilate methanol. Glycerol was inhibitory to growth at high concentrations. However, product yield continued to increase as the glycerol concentration was increased. In chemostat culture, dissolved oxygen concentration influenced product yield independently of any detectable influence on cell growth.     

重组巴斯德毕赤酵母发酵生产内切几丁质酶的培养条件优化

探讨重组巴斯德毕赤酵母发酵生产内切几丁质酶的最适培养条件,以期获得最佳的内切几丁质酶活力。以内切几丁质酶活力为指标,通过部分因子试验设计以及响应面法优化确定重组巴斯德毕赤酵母高产内切几丁质酶的最适培养条件。部分因子试验设计筛选的影响重组巴斯德毕赤酵母高产内切几丁质酶的3个关键因子为甲醇、油酸和吐温-80。响应面法优化的上述3个关键因子的最佳浓度分别为0.71%、0.086%和0.31%。重组巴斯德毕赤酵母发酵生产内切几丁质酶的最适培养条件为：酵母膏1%、酵母氮碱（YNB）1.34%、蛋白胨2%、甲醇0.71%、油酸0.086%、吐温-80 0.31%、PTM₁ 0.8%、pH 6.0。在上述培养条件下,重组巴斯德毕赤酵母产内切几丁质酶的活力高达30.92U/mL。与未优化前相比,酶活力提高了1.44倍。研究结果为内切几丁质酶的产业化生产和应用奠定了良好基础。     

Characterization and high‐yield production of non‐N‐glycosylated recombinant human BCMA‐Fc in Pichia pastoris

B‐cell maturation antigen (BCMA) fused at the C‐terminus to the Fc portion of human IgG1 (BCMA‐Fc) blocks B‐cell activating factor (BAFF) and proliferation‐inducing ligand (APRIL)‐mediated B‐cell activation, leading to immune disorders. The fusion protein has been cloned and produced by several engineering cell lines. To reduce cost and enhance production, we attempted to express recombinant human BCMA‐Fc (rhBCMA‐Fc) in Pichia pastoris under the control of the AOX1 methanol‐inducible promoter. To produce the target protein with uniform molecular weight and reduced immunogenicity, we mutated two predicted N‐linked glycosylation sites. The secretory yield was improved by codon optimization of the target gene sequence. After fed‐batch fermentation under optimized conditions, the highest yield (207 mg/L) of rhBCMA‐Fc was obtained with high productivity (3.45 mg/L/h). The purified functional rhBCMA‐Fc possessed high‐binding affinity to APRIL and dose‐dependent inhibition of APRIL‐induced proliferative activity in vitro through three‐step purification. Thus, this yeast‐derived expression method could be a low‐cost and effective alternative to the production of rhBCMA‐Fc in mammalian cell lines.     

重组毕赤酵母高密度发酵生产内切型纤维素酶的条件优化

为优化内切型纤维素酶高密度发酵工艺条件,在7.5L发酵罐高密度发酵条件下,研究内切型纤维素酶表达量以及毕赤酵母胞外蛋白酶合成水平的影响因素。研究表明:经340mL甘油补料发酵后,在甲醇诱导阶段,pH为5.0,温度为25℃,利用甲醇检测流加控制器控制甲醇体积分数为0.33%～0.35%时,EGI表达量可达421.1IU/mL,比采用固定甲醇流加速率的发酵方法提高了1.49倍。     

Expression of a recombinant elastin‐like protein in pichia pastoris

The translation of highly repetitive gene sequences is often associated with reduced levels of protein expression and may be prone to mutational events. In this report, we describe a modified concatemerization strategy to construct a gene with enhanced sequence diversity that encodes a highly repetitive elastin‐like protein polymer for expression in Pichia pastoris. Specifically, degenerate oligonucleotides were used to create a monomer library, which after concatemerization yielded a genetically nonrepetitive DNA sequence that encoded identical pentapeptide repeat sequences. By limiting genetic repetition, the risk of genetic deletions, rearrangements, or premature termination errors during protein synthesis is minimized. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2009     

纤维连接蛋白C端肝素结合域多肽在毕赤酵母中的表达、纯化及鉴定

为在毕赤酵母中表达纤维连接蛋白C端肝素结合域(Fibronectin C-terminal heparin-binding domainFNCHBD)多肽并研究其功能,通过PCR技术扩增FNCHBD目的基因,将目的基因与T载体连接,经测序正确后,插入pAo815SM酵母表达载体增加基因拷贝数,然后酶切克隆入酵母表达载pPIC9K;将重组质粒Sal I酶切线性化后转化毕赤酵母菌株,筛选工程菌,经甲醇诱导表达,用SDS-PAGE检测发酵上清液,表明有重组蛋白FNCHBD多肽的高表达,表达产物通过离心、超滤、离子交换层析纯化,纯化产物通过SDS-PAGE、Western blotting印迹、质谱及肝素亲和层沉析对表达产物进行鉴定。结果表明利用酵母工程菌成功表达和纯化了FNCHBD多肽,多肽的分子量接近32 kDa,纯化产物的纯度可达95%以上,能被FN多克隆抗体特异识别且具有多肽肝素结合活性,为后续结构及功能的研究奠定基础。     

Recombinant production of the human aquaporins in the yeast Pichia pastoris (Invited Review)

Abstract

Aquaporins are water facilitating proteins embedded in the cellular membranes. Such channels have been identified in almost every living organism – including humans. These proteins are vital molecules and their malfunction can lead to several severe disorders and diseases. Hence, an increased understanding of their structure, function and regulation is of the utmost importance for developing current and future drugs. Heading towards this goal, the first problem to overcome is to acquire the proteins in sufficient amounts to enable functional and structural characterization. Using a suitable host organism, large amounts of target molecules can possibly be produced, but for membrane proteins limitations are frequently encountered. In the work described here, we have produced the 13 human aquaporins (hAQPs) in one of the most successful hosts for recombinant overproduction of eukaryotic proteins; the yeast Pichia pastoris, in order to explore the underlying bottleneck to a successful membrane protein production experiment. Here we present exceptional yield of hAQP1, whereas some other hAQPs were below the threshold needed for scaled up production. In the overproduction process, we have established methods for efficient production screening as well as for accurate determination of the initial production yield. Furthermore, we have optimized the yield of low producing targets, enabling studies of proteins previously out of reach, exemplified with hAQP4 as well as the homologue PfAQP. Taken together, our results. present insight into factors directing high production of eukaryotic membrane proteins together with suggestions on ways to optimize the recombinant production in the yeast P. pastoris.     

灵芝免疫调节蛋白(Lz-8)在毕赤酵母中的表达及其免疫活性鉴定

真菌免疫调节蛋白家族(Fungi immunoregulatory proteins,FIPs)各成员所具有的免疫调节和抗肿瘤活性已被广泛研究。本研究利用毕赤酵母表达系统对其成员Lz-8进行了重组表达。以毕赤酵母突变株GS115为表达宿主细胞,PCR和DNA测序结果均显示Lz-8的cDNA已被成功地整合入酵母基因组。聚丙烯酰胺凝胶电泳(SDS-PAGE)、激光解析飞行时间质谱(MALDI-TOF-MS)和免疫学实验均被用于重组表达蛋白的检测。实验结果表明Lz-8在毕赤酵母表达系统中得到成功表达,在SDS-PAGE中可观察到分子量为14000D的单一条带,MALDI-TOF-MS的实验结果显示rLz-8的分子量为12722D。在相关的免疫学实验中,rLz-8可引起绵羊血红细胞凝集,但对人血4种血型的红细胞并没有凝集作用,rlz-8还可诱导巨噬细胞吞噬作用,均与其他报道中的实验结果吻合。以上结果表明,本实验已成功地利用毕赤酵母表达系统对Lz-8进行重组表达。     

一种融合抗体ScFv-Fc通用表达载体的构建

为了构建一个可供自由替换的ScFv区,表达人小分子融合抗体ScFv-Fc的通用载体,利用RT-PCR技术扩增人抗体IgG1的Fc片段克隆至毕赤酵母表达载体pPICZα,将一段人工合成的互补寡核苷酸链插入重组载体pPICZα/Fc中Fc区的上游,引入2个可供小分子抗体ScFv-Fc的ScFv区自由替换的限制性酶切位点。分别扩增人抗狂犬病毒以及抗乙型肝炎表面抗原的ScFv片段,克隆至已构建的通用载体pPICZα/Fc,在毕赤酵母中诱导表达。进一步在1L条件下对活性抗体进行发酵,并利用protein A亲和层析柱进行纯化。应用酵母基因组PCR、ELISA、Western blotting、活性检测等试验对此小分子抗体的表达进行生物学及免疫学分析。结果表明具有狂犬病毒抗原结合活性以及乙肝表面抗原结合活性的人源抗体分子均获得成功表达,1L发酵条件下表达量达到20~30mg/L, protein A亲和层析纯化后纯度＞95%。研究构建了可用于功能性抗体分子ScFv-Fc筛选和表达的通用载体并对其发酵、纯化条件进行了摸索,为重组抗体分子诊断、治疗试剂的开发以及抗体的人源化奠定了物质基础。